S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:PODD - Insulet Stock Price, Forecast & News

$188.76
-2.70 (-1.41 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$187.10
Now: $188.76
$191.66
50-Day Range
$169.34
MA: $177.74
$191.39
52-Week Range
$73.78
Now: $188.76
$192.43
Volume359,400 shs
Average Volume529,942 shs
Market Capitalization$11.67 billion
P/E Ratio3,775.20
Dividend YieldN/A
Beta1
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.33 per share
Book Value$3.59 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$11.67 billion
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier earned $192.12 million during the quarter, compared to analysts' expectations of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. The firm's quarterly revenue was up 27.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PODD?

17 brokerages have issued 12 month target prices for Insulet's stock. Their forecasts range from $100.00 to $200.00. On average, they anticipate Insulet's stock price to reach $158.82 in the next year. This suggests that the stock has a possible downside of 15.9%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

News coverage about PODD stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insulet earned a news impact score of 3.0 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Insulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Splunk (SPLK), Tandem Diabetes Care (TNDM), salesforce.com (CRM), Veeva Systems (VEEV), Roku (ROKU) and Trade Desk (TTD).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.02%), Tributary Capital Management LLC (0.02%), First Hawaiian Bank (0.01%), Tocqueville Asset Management L.P. (0.01%), Polianta Ltd (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P. and Tributary Capital Management LLC. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which major investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Polianta Ltd, IFM Investors Pty Ltd, Sciencast Management LP, Alpine Global Management LLC, First Hawaiian Bank, OLD National Bancorp IN and Cerebellum GP LLC. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $188.76.

How big of a company is Insulet?

Insulet has a market capitalization of $11.67 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  615 (Vote Outperform)
Underperform Votes:  539 (Vote Underperform)
Total Votes:  1,154
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel